Tofersen
233AS102
Phase 3 small_molecule completed
Quick answer
Tofersen for ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation is a Phase 3 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IONIS PHARMACEUTICALS INC
- Indication
- ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed